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BRIEF COMMUNICATION
Novel cerebrotendinous xanthomatosis mutation
causes familial early dementia in Colombia
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Introduction: Cerebrotendinous xanthomatosis is an infrequent cause of dementia. It is an autosomal 
recessive disorder with clinical and molecular heterogeneity. 
Objective: To identify the presence of a possible mutation in a Colombian family with several affected 
siblings and clinical characteristics compatible with cerebrotendinous xanthomatosis associated to 
early dementia.
Materials and methods: We studied a series of cases with longitudinal follow-up and genetic analysis.
Results: These individuals had xanthomas, mental retardation, psychiatric disorders, behavioral changes, 
and multiple domains cognitive impairment with dysexecutive dominance that progressed to early 
dementia. CYP27A1 gene coding region sequencing revealed a novel mutation (c.1183_1184insT).
Conclusion: The mutation found in this family is responsible for the described dementia features. Early 
identification of familial history with mental retardation, xanthomas and cognitive impairment might 
prevent the progression to this treatable type of dementia. Even though this mutation lies in the most 
frequently mutated codon of CYP27A1 gene, it has not been reported previously.
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Nueva mutación para xantomatosis cerebrotendinosa causa demencia familiar temprana           
en Colombia
Introducción. La xantomatosis cerebrotendinosa es una causa poco frecuente de demencia. Es un 
trastorno autosómico recesivo con heterogeneidad clínica y molecular.
Objetivo. Identificar la presencia de una posible mutación en una familia colombiana con varios 
hermanos afectados y con características clínicas indicativas de xantomatosis cerebrotendinosa 
asociada a demencia precoz. 
Materiales y métodos. Se estudió una serie de casos, con seguimiento longitudinal y análisis genético.
Resultados. Estos individuos tenían xantomas, retraso mental, trastornos psiquiátricos, cambios 
de comportamiento y alteraciones cognitivas de múltiples dominios con predominio de la disfunción 
ejecutiva, que progresaron a demencia temprana. Se identificó una nueva mutación (c.1183_1184insT) 
en el gen CYP27A1.
Conclusión. La mutación encontrada en esta familia es responsable de la demencia descrita en los 
sujetos de estudio. La detección temprana de una historia familiar con retraso mental, xantomas y 
deterioro cognitivo, podría prevenir la progresión de este tipo de demencia tratable. A pesar de que 
esta mutación se encuentra en el codón más frecuentemente mutado del gen CYP27A1, no se había 
informado anteriormente.
Palabras clave: xantomatosis, esquizofrenia, demencia, genética.
doi: http://dx.doi.org/10.7705/biomedica.v35i4.2690
Cerebrotendinous xanthomatosis is an autosomal 
recessive disorder of bile acid biosynthesis caused 
by the abnormal deposition of cholestanol in the 
body due to a deficiency of the mitochondrial 
enzyme 27-sterol hydroxylase (CYP27). CYP27A1 
gene mutations are the only cause associated with 
cerebrotendinous xanthomatosisto date (1). The 
first mutation in the CYP27A1 gene was described 
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in 1991 (2), but clinical characteristics were first 
noted by van Bogaert in 1937 (3). The clinical 
picture depends on the location of the deposits 
of cholestanol from childhood to adulthood. The 
brain, tendons and crystalline lens are the tissues 
primarily affected. Therefore, common clinical 
findings in cerebrotendinous xanthomatosisinclude 
chronic diarrhea in childhood, psychomotor retar-
dation, tendon xanthomas, juvenile cataracts, and 
progressive dementia with cerebello-pyramidal 
signs, osteoporosis and premature atherosclerosis 
(4). The diagnosis can be performed based on the 
determination of serum levels of cholestanol or 
based on the genetic study by sequencing gene 
CYP27A1. The findings of magnetic resonance 
imaging (MRI) typically include bilateral and 
symmetric hyperintensity in T2 of the dentate 
nuclei, periventricular white matter, basal ganglia 
and brainstem in addition to widespread cortico-
subcortical atrophy (5). Clinical improvement of 
individuals with cerebrotendinous xanthomatosis 
following chenodeoxycholic acid treatment has 
been reported (6).
CYP27A1 is located on human chromosomal region 
2q35. It has nine exons spanning 18.6 kb of DNA; its 
coding DNA sequence is 1596 bp long and encodes 
a 531aa protein (CYP27). At present, 60 mutations 
have been identified in nearly 317 patients (7-15), 
and no phenotype-genotype correlation has been 
observed (14).
Gallus, et al., described that about half of the 
mutations have been described in the exon 6-8 
tracts of the CYP27A1 gene. From the total of 
mutations, 45% are missense which together with 
nonsense mutations add up to about 2/3 of the total 
reported to date (10). 
Here we report a cerebrotendinous xanthomatosis 
Colombian family with four affected siblings. Three 
of them presented with cognitive impairment and 
dementia. Clinical features, and neurological, 
neuropsychological, imaging and genetic findings 
in this family were analyzed. This entity was 
described clinically in another Colombian family 
in 2003, but without genetic confirmation (Cabrera 
D, Franco A, Builes C. Características clínicas 
de una familia antioqueña con xantomatosis 
cerebrotendinosa. Acta Neurol Colomb. 2003;19. 
Cartel 68. Memorias, VI Congreso Colombiano 
de Neurología). This study is the first longitudinal 
study of cognitive impairment of the cerebro-
tendinous xanthomatosis. In addition, mutation 
reported is the first one identified in Colombia 
causing this disease.
Materials and methods
This family is originally from Antioquia, northwest 
Colombia. Extension of the pedigree from the index 
case revealed three more affected siblings. The 
parents were consanguineous and no previous 
report of the disease in the family was described 
(figure 1). Four out of five siblings were affected. All 
affected individuals and their relatives participating 
in this study signed an informed consent form at the 
beginning of the study, which was approved by the 
ethics committee from Universidad de Antioquia. 
This family has been followed since 2005 in the 
Grupo de Neurociencias de Antioquia, Facultad 
de Medicina, Universidad de Antioquia, which is a 
reference center for research in neurodegenerative 
diseases and hereditary dementias in Colombia. 
These participants belonged to an undergoing 
study of family movement disorders and they 
were followed up longitudinally during a period 
of approximately six years starting when they 
were around 50 years old. Genetic analysis, 
electroencephalogram, electromyography and four-
limb nerve conduction velocity, as well as brain MRI 
were performed.
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Figure 1. Pedigree of a Colombian family with cerebrotendinous 
xanthomatosis. Square symbols represent men, circles represent 
women. A double line indicates the consanguineous marriage 
that originated the four siblings affected. A slash on a symbol 
indicates a deceased person. 
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The follow-up examination included medical and 
neuropsychological assessment. The clinical history 
and the medical and neurological examinations 
were performed by neurologists and trained gen-
eral practitioners. Neuropsychological tests were 
applied by independent neuropsychologists and 
trained personnel without knowledge of diagnosis 
or genetic status. The Grupo de Neurociencias de 
Antioquia Complete Dementia Protocol included the 
Consortium to Establish a Registry for Alzheimer’s 
Disease (CERAD) neuropsychological test battery 
with additional neuropsychological tests, validated 
for the Colombian population in subjects over 50 
years of age, as previously reported in other Grupo 
de Neurociencias de Antioquia studies (16).
Tests were applied as follows: Mini-mental state 
examination, Rey-Osterrieth complex figure (recall), 
list of words, list of words (intrusions), list of words 
(recall), list of words (intrusions recall), list of words-
recognition “Yes”, list of words-recognition “No”, 
recall of line-drawings, naming, phonological verbal 
fluency “F”, constructional praxis, Rey-Osterrieth 
complex figure (copy), Raven’s test (part A and 
B), arithmetic test, visual “A” cancellation test 
(omissions), visual “A” cancellation test (time), trial 
making test-part A (corrects), trial taking test-part A 
(time), Wisconsin card sorting test (perseverative 
errors), Wisconsin card sorting test (correct), 
Wisconsin card sorting test (error), Wisconsin card 
sorting test (categories), and Wisconsin card sorting 
test (conceptual). Clinically significant cognitive 
decline was considered if neuropsychological test 
scores were 1.5 standard deviations (SD) away 
from the mean score (17) in at least one test 
on any cognitive domain adjusted for age and 
education level.
Analysis of the CYP27A1 gene
Primers to amplify the nine exons of the coding 
region of the CYP27A1 gene were designed 
using the application primer3 available at http://
frodo.wi.mit.edu/. These included the exon-intron 
boundaries. Primer sequences are available upon 
request. PCR fragments were amplified in a 25 
μl volume using 0.33 μM of each primer, 0.2 mm 
each dNPT, 1.5 mm Mg2+, 1X buffer, 0.02 U of Taq 
polymerase (Biolase-Bioline), and 30 ng of genomic 
DNA. DNA samples from index case and case 3 
were used to amplify all exons and then underwent 
nucleotide sequence using an Applied Biosystems 
genetic analyzer 3130. Restriction analysis was 
done for mutation c.1183_1184 insT. This insertion 
destroys the target for the restriction enzyme AciI. 
Five units were used to digest PCR fragments at 
37oC overnight and according to manufacturer’s 
recommendations (New England Biolabs®). PCR 
and digestion products were resolved in 2% agar-
ose gel electrophoresis and stained with ethidium 
bromide. Sixty control chromosomes were tested 
for this mutation.
Results
A family of five siblings, four of them affected with 
cerebrotendinous xanthomatosis, was identified. 
The findings in three of these cases (index case, 
case 2 and case 3) were described. These indi-
viduals had cognitive impairment and dementia 
and it was possible to do follow-up. In case 4, some 
clinical findings were identified by family interview.
Clinical, radiological, and neurophysiological char-
acteristics of the three cases are summarized in 
table 1.
Neurological assessment
Index case. The index case (male) presented fatty 
tumors: Xanthoma tuberous in the knee and tendon 
xanthoma in Achilles tendon, which were noticeable 
at age 25 (figure 2). Depression, anxiety attacks, 
akathisia, and behavior changes were evident at 
age 37. Mild multidomain cognitive impairment 
was evident at age 57. Examination of the nervous 
system showed a postural tremor of the right hand 
with slight rigidity. All deep reflexes were sharp and 
plantar reflexes were normal. Gait was normal in this 
patient. He suffered a severe traumatic brain injury 
when he was 60 years old. Since then, the patient 
is hemiplegic and inevaluable by neuropsychology, 
and it was not possible to continue the follow-up.
Case 2.This female patient had bilateral cataracts, 
which were removed at age 15. She had poor 
cognitive functioning from childhood and missed 
several school years. At 40 years, marked rigidity in 
left hemibody, unsteady gait, dysarthria, depression, 
irritability and visual hallucinations appeared. She 
had a hip fracture at 48 years and Achilles tendon 
xanthomas were found at 55. Clinical examination 
revealed ataxia, hyperactive reflexes, and extensor 
plantar response. She presented Parkinsonism at 
40. Chronic intermittent diarrhea started at age 
59. She also showed a systemic deterioration 
and cognitive impairment added to her previous 
cognitive deficit and she died due to aspiration 
pneumonia at 64.
Case 3. This male patient presented with episodes 
of seizures at the age of 4. He also had learning 
difficulties. At age 30, Achilles and patellar tendon 
566
Biomédica 2015;35:563-71Giraldo-Chica M, Acosta-Baena N, Urbano L, et al.
xanthomas were found. At 40, he started to present 
psychiatric symptoms. A few years later, he had 
tremor and rigidity of the left hand. Parkinsonism 
was diagnosed at 41 and the patient underwent a 
therapeutic test with levodopa (750 mg/day) since 
age 49. The withdrawal of levodopa worsened the 
stiffness. Clinical and neurological examination 
revealed a poorly expressive face, resting tremor, 
hypereactive tendon reflexes, and extensor plantar 
response. Gait was slow and rigid with short 
steps. At 62, he suffered from refractory epilepsy 
and died at 65 from aspiration pneumonia during 
a status epilepticus.
Case 4. This was a male patient who died at 47 
years.Clinical details of the fourth case were 
reconstructed by familial interview; very scarce 
information could be obtained about this patient. 
He had normal cognition, worked in a textile factory, 
and presented Achilles tendon xanthomas at age 
30.He had a history of arterial hypertension and 
depressive symptoms after marital separation. He 
suffered subsequent stroke at 45. He was ran over 
by a car two years later and died.
Genetic analysis
Data suggested that the four affected individuals in 
this Colombian family had conditions consistent with 
the diagnosis of cerebrotendinous xanthomatosis. 
PCR products ruled out homozygous deletions 
of CYP27A1 exons. Affected individuals were 
homozygous for a novel CYP27A1 gene mutation 
at exon 6, which truncates the heme domain of the 
protein. Of the 25% expected, 80% of the siblings 
were affected.
Sequence analysis revealed an insertion of nucleo-
tide T in between positions 1183 and 1184 (from the 
start codon) in exon 6, c.1183_1184insT (figure 3).
Restriction analysis showed that all three affected 
available subjects were homozygous for such a 
mutation. Consistent with autosomal recessive 
Table 1. Characteristics of three cerebrotendinous xanthomatosis 
patients from a Colombian family 
Variable Index 
case 
Case 2 Case 3
Gender
Xanthomas (age of onset)
Cataracts
Diarrhea 








Cognitive impairment (age of onset)
 Mild cognitive impairment
 Dementia 








Age of death 
MRI (age)
 MRI supratentorial atrophy
 MRI infratentorial atrophy
 MRI parenchymal lesions: 
  Caudate nucleus atrophy
  Periventricular microangiopathic








































































































The symbols + and - denote the presence or absence of said characteristic, 
respectively. The age of onset of the variables was recorded when it 
was available.
MRI: magnetic resonance imaging, EMG: electromyography,
EEG: electroencephalogram, ND: No data
Figure 2. Knee xanthomas of the index case. The index case 
presented with fatty tumors on both Achilles and knee tendons, 
which were noticeable at age 25.
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inheritance, the mother was a carrier for this 
mutation. None of the control chromosomes 
carried the mutation reported here. The mutation 
c.1183_1184 insT is predicted to cause the 
p.R395fsX412 substitution at the protein level. 
Besides, a premature stop codon is generated 17 
codons downstream from codon 395. The new 
truncated protein is missing the heme binding site. 
It is worth mentioning that the codon involved in the 
mutation reported here is the one most frequently 
mutated in this gene http://grenada.lumc.nl/LOVD2/
ctx/home.php?select_db=CYP27A.
Findings of magnetic resonance, 
electromyography and electroencephalogram
Index case brain MRI showed discrete frontal and 
parietal atrophy, with periatrial microangiopathy. A 
T1-weighted sequence showed two hypointense 
lesions of the choroid plexus. Case 2 showed 
symmetric atrophy of the frontal and temporal 
lobes. Additionally, a discrete cerebellar atrophy 
was observed. Case 3 showed atrophy of the 
frontal lobes, temporal lobes and caudate nucleus. 
A T1-weighted sequence showed two hypointense 
lesions of the choroid plexus compatible with 
xanthomas (figure 4). Electromyography and nerve 
four-limb conduction velocity were normal in the 
three patients tested. The electroencephalogram 
(EEG) showed a diffuse slowing in all subjects.
Neuropsychological evaluation
Since the beginning of monitoring cognitive profiles, 
the three subjects presented cognitive impairment. 
Cases 2 and 3 had a significantly lower perfor-
mance. Index case had a better premorbid level, 
but unlike the cases 2 and 3, he did not develop 
dementia until the follow-up was possible. The most 
relevant tests according to each neuropsychological 
profile can be observed in figure 5.
Discussion
Antioquia in Colombia is famous in the world due 
to its high prevalence of familial dementia, with 
the greatest focus of familial Alzheimer’s disease 
mutation E280A in the presenilin 1. We report 
a new mutation in a family with a rare hereditary 
dementia due to cerebrotendinous xanthomatosis 
in this same region of Colombia. 
This is the first study in Colombia aimed at charac-
terizing cerebrotendinous xanthomatosis, from both 
phenotypic and genetic points of view. Affected 
individuals presented clinical characteristics 
compatible with cerebrotendinous xanthomatosis. 
CYP27A1 gene sequence analysis uncovered a 
novel mutation associated with cerebrotendinous 
xanthomatosis. It is predicted that the mutation 
c.1183_1184insT leads to the change of an Arg 
residue for a Leu at position 395. A premature 
stop codon is originated 17 residues downstream. 
Therefore, the mutant enzyme is predicted to miss 
the heme binding site (11). Interestingly, codon 
395 of CYP27A1 has been previously reported 
as participating in three other mutations causing 
cerebrotendinous xanthomatosis (2,18,19). 
C T G C T TG G GA G
Figure 3. Molecular analysis of CYP27A1 gene exon 6 Partial 
sequence of exon6/intron6 boundaries. The arrow indicates the 
insertion of a T in between CpG, which are the final nucleotides 
of exon 6. Intron 6 starts at GpTpA. 
Figure 4. Brain MRI of case 3 with hypointensities of choroids 
plexus.
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Our report concerns the fourth mutation in this 
codon, indicating a hot spot codon for mutational 
events in CYP27A1 gene. With the mutation 
reported here, frameshift mutations at this gene 
account for 20% of the defects associated with 
cerebrotendinous xanthomatosis. The observation 
that a decanucleotide is inserted in a cerebro-
tendinous xanthomatosis patient (10) and that 
exactly the same decamer deletion appeared in 
another patient (20) suggests a possible mechanism 
of unequal crossover in CYP27A1 gene. This might 
happen as a result of missalignment of non-allelic 
sequences (21,22). The mutation of this decamer, 
in addition to the fourth mutation of codon 395 
reported here, points to two CYP27A1 mutational 
hot spots. Taking into account that the mutation 
c.1183_1184insT involves the last two nucleotides 
of exon 6, it was supposed that the splicing site was 
affected. Prediction of modification of the splice site 
was carried out with NetGene2 (23,24) server. It 
was observed that when using the normal sequence, 
the splice would occur with 80% confidence and 
when using the mutant sequence it would occur 
with 70% confidence (data not shown). This analysis 
is in line with our conclusion about the absence of 
the heme binding site, either by this mechanism or 
by the premature stop codon at position 412 of the 
protein. Experimental data could confirm whether 
the splicing does occur or not.
One of such experimental approaches could be 
RNA isolation followed by reverse transcriptase 
processing to generate a PCR template (cDNA). 
This PCR should flank exons 5 and 6 and then 
by gel electrophoresis resolve the amplicon sizes. 
The patients should present a homozygous larger/
shorter PCR fragment compared to controls or 
unaffected family members. Another approach, 
which could complement the previous one, could 
be sequencing the PCR fragment obtained from the 
cDNA. This would identify where the precise splice 
did occur in relation to the mutation reported here.
Even though a wide variety of clinical and endo-
phenotypes have been observed, qualitative 
homogeneity has been found for the presence of 
xanthomas, Parkinsonism, psychiatric symptoms, 
dysexecutive cognitive impairment and supratentorial 
atrophy. However, the age of onset for each of these 
manifestations is heterogenous. Thus, the onset 
of tendon xanthomas and both neurological and 
psychiatric symptoms ranged widely, and cataracts 
were present only in one individual (case 2). Chronic 
diarrhea from childhood may be the earliest clinical 
manifestation of cerebrotendinous xanthomatosis, 
but in this family this symptom was present when 
individuals were over 50 years old, unlike other 
studies on cerebrotendinous xanthomatosis (10,15). 
Parkinsonism was observed in three of the four 
affected individuals (range of onset: 40-55, average: 
45) with poor response to levodopa. Parkinsonism 
is an uncommon symptom, but cerebrotendinous 
xanthomatosis patients associated with this extra-
pyramidal sign have been reported to date (7,8, 
22,25-29). Pyramidal symptoms were observed 
in two individuals (case 2 and 3). Other abnormal 
movements were not observed. The age of onset 





















































1 2 3 4
1 2 3 4 5
NAMING
CERAD Word recog
CERAD constructional WCST- perseverative responses
Rey figure (Copy) Rey figure (recall)
Phonemic fluency (FAS)
Figure 5. Neuropshycological assessment: Variability of cognitive 
domains during clinical progression in three siblings with 
cerebrotendinous xanthomatosis.
Since the first evaluation, the Z score in these cognitive 
domains decreased progressively. 
569
Biomédica 2015;35:563-71 Cerebrotendinous xanthomatosis mutation in Colombia
Mental retardation has been described in cerebro-
tendinous xanthomatosis (15). In cases 2 and 3, a 
worse neuropsychological performance was found 
since the first evaluation (at 52 and 53 years 
old, respectively) possibly because the onset 
of cognitive impairment was earlier and higher 
in these subjects compared to the index case. 
Cognitive profiles of these two patients were 
highly affected by their cognitive impairment at 
baseline, which made all their performances lower 
than expected for their age group and school 
level. Therefore, both patients had probably low 
intelligence from early infancy and began to exhibit 
more deterioration. For the index case, previous 
cognitive level was normal and mild cognitive 
impairment was observed afterward. We could 
not detect the onset of dementia in this subject, 
because of his severe head trauma.
In three individuals analyzed, praxic-mnesic 
abilities were altered, but the deterioration profile 
was predominantly dysexecutive, unlike the 
expected impairment on Alzheimer’s disease, 
where the deterioration is predominantly amnesic 
from the beginning.
The psychiatric manifestations in cerebrotendinous 
xanthomatosis follow a bimodal pattern. They 
appear during childhood or adolescence with 
learning impairments, mental retardation, behav-
ioral changes, personality disorders or they appear 
when the disease has progressed. Dementia and 
other psychiatric manifestations are the result of 
the alterations in multiple neuronal networks in 
the white matter with myelin-lipid substrate and 
demyelinitization disorders (30-35).
To date, different cerebrotendinous xanthomatosis 
demential syndrome profiles have been reported. 
One of these profiles is the frontotemporal 
dementia and/or cortico-subcortical compromise 
which are characterized by a poor performance in 
the executive function (30) and neuropsychiatric 
features (35).
A previous case report mentions a 53 year-old 
woman with predominant frontal dysfunction, 
behavioral alterations and poor performance 
on executive tasks with preservation of visual-
constructive abilities. This patient fulfilled the 
criteria for frontotemporal lobe dementia (30). 
Another case has been reported in a woman 
who, at age 38, began to present changes in 
personality and apathy, and dementia syndrome 
with frontal predominance (36). Some other cases 
were also compatible with a clinical diagnosis of 
frontotemporal dementia in genetically confirmed 
cerebrotendinous xanthomatosis (35).
MRI findings were heterogenous. Thus, all three 
available affected individuals showed supraten-
torial atrophy; only one subject (case 2) presented 
infratentorial atrophy. Her clinical examination 
disclosed ataxia. Case 3 presented caudate nucleus 
atrophy. He had Parkinson’s symptoms, but had no 
other abnormal movements. Hypointense lesions 
of the choroid plexus were observed in index case 
and case 3 as well. Imaging findings commonly 
described in cerebrotendinous xanthomatosis are 
nonspecific supratentorial atrophy and deep white 
matter changes; more typical hyperintense lesions 
were seen on T2-weighted images in the dentate 
nucleus, globus pallidus, substantia nigra, and 
inferior olive, which extended into adjacent white 
matter as the disease progressed (37).
Cholestanol could not be measured in any of 
the patients and none received treatment with 
chenodeoxycholic acid as neither the test nor the 
drug are available in Colombia. These patients 
received antidepressants and antipsychotics with 
improvement in their symptoms. 
This family case is important for being the first 
genetically identified in our country. All the 
genetically studied cases were homozygous and 
there was a high percentage (80%) of subjects 
affected, despite being an autosomal recessive 
disorder.
We were able to perform a neurological and neuro-
psychological follow-up, a verification of deterioration 
over time and to describe some characteristics of 
dysexecutive cognitive performance that differ from 
the amnestic profile found in Alzheimer’s disease.
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